[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"systemic-autoimmune-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:systemic-autoimmune-diseases":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100614362","the-rheumsafer-study-improving-medication-appropriateness-in-people-with-rheumatic-conditions-100614362",false,"NCT07278609","The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions","Inclusion Criteria:\n\n* Aged ≥60\n* Followed by a rheumatologist at MUHC for an inflammatory arthritis (such as rheumatoid arthritis, psoriatic arthritis, spondyloarthritis), a systemic autoimmune rheumatic disease (such as systemic lupus erythematosus, inflammatory myositis, systemic sclerosis, antiphospholipid antibody syndrome, Sjogren syndrome, systemic vasculitis), or another chronic musculoskeletal or rheumatic condition (such as crystal arthritis and osteoarthritis)\n* Currently taking ≥5 regular medications and ≥1 PIM\n* Anticipated ongoing clinical follow-up in rheumatology at an interval of every 3-9 months\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Acute life-threatening illness or life expectancy \\\u003C12 months","ALL","60 Years",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","The goal of this prospective observational quality improvement study is to determine if a physician tool, MedSafer, combined with educational brochures for patients, can help to reduce the use of 'potentially inappropriate medications' (PIMs) in adults aged 60 and over with rheumatic conditions and polypharmacy (taking 5 or more regular medications).\n\nResearchers will follow participants during usual rheumatic disease care. They will compare the rate of PIM deprescribing (stopping medications or reducing the dose) before and after the introduction of the following interventions:\n\n* MedSafer reports provided to treating physicians\n* EMPOWER consumer brochures provided to participants\n\nParticipants will complete 4 study visits over 18-20 months during which researchers will collect information on medication changes, serious adverse events (emergency visits or hospitalizations), and quality of life.",[23,24,25,26,27,28],"Rheumatic Diseases","Inflammatory Arthritis","Systemic Lupus Erthematosus (SLE)","Vasculitis","Muskuloskeletal Diseases","Systemic Autoimmune Diseases",[30,31,23,32],"Deprescribing","Potentially inappropriate medications","Polypharmacy","RECRUITING","2026-04-27",{"date":36,"type":37},"2026-05-01","ACTUAL",{"date":39,"type":37},"2025-10-29",{"date":41,"type":19},"2028-06-30",{"name":43,"class":44},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100574060","phase-4-prophylactic-tranexamic-acid-reduces-postpartum-hemorrhage-100574060","NCT06754371","Prophylactic Tranexamic Acid Reduces Postpartum Hemorrhage","Safety and Efficacy of Prophylactic Tranexamic Acid in Reducing Postpartum Hemorrhage After Cesarean Delivery in Women with Systemic Autoimmune Disease：A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients undergoing cesarean delivery\n2. Preoperative diagnosis of pregnancy with systemic autoimmune diseases (systemic lupus erythematosus, antiphospholipid syndrome, systemic sclerosis, Sjogren's syndrome, rheumatoid arthritis, undifferentiated connective tissue disease)\n3. Obtain informed consent.\n\nExclusion Criteria:\n\n1. intrauterine fetal death\n2. Existing\u002Fprevious history of thromboembolism\n3. Hemorrhagic disease, significant prenatal bleeding\n4. Balloon placement of internal iliac artery\n5. Allergic to tranexamic acid\n6. Severe renal insufficiency (serum creatinine \\>451μmol\u002FL or blood urea nitrogen \\>20mmol\u002FL)\n7. Epilepsy","FEMALE","18 Years","50 Years",{"count":57,"type":19},276,"INTERVENTIONAL",[60],"PHASE4","Postpartum hemorrhage (PPH) is the most significant leading cause of pregnancy-related mortality in high-risk cesarean delivery women. Systemic autoimmune diseases are associated with adverse pregnancy outcomes (APOs), including PPH, preeclampsia, thromboembolism, abortion, and intrauterine growth restriction. The incidence of PPH in women with systemic lupus erythematosus has been reported to be as high as 34%. Prevention of PPH is the key to reduce complications in high-risk women. In recent years, a large number of clinical studies have confirmed that the early preventive use of tranexamic acid(TXA) can reduce the amount of blood loss, the need for additional uterine contraction agents, the risk of blood transfusion, and maternal adverse outcomes, and do not increase the risk of thromboembolic events, which can be used to prevent PPH. However, the study population of TXA is mainly low-risk puerpera, and there is still a lack of relevant research on TXA used in pregnant women with systemic autoimmune diseases. The purpose of this study was to evaluate the safety and efficacy of TXA in preventing postpartum hemorrhage after cesarean delivery in women with systemic autoimmune disease, as well as the maternal and neonatal risks associated with systemic autoimmune disease, to provide evidence for clinical practice and further research.",[63,28],"Postpartum Hemorrhage",[65,66,67,68],"postpartum hemorrhage","systemic autoimmune disease","cesarean delivery","thromboembolism","2025-03-13",{"date":71,"type":37},"2025-03-17",{"date":73,"type":37},"2025-01-06",{"date":75,"type":19},"2027-06",{"name":77,"class":44},"RenJi Hospital"]